This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Piper Sandler Keeps Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

Tipranks - Tipranks - Wed Jun 3, 6:52AM CDT

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Jazz Pharmaceuticals, with a price target of $301.00.

Claim 55% Off TipRanks

According to TipRanks, Amsellem is a 5-star analyst with an average return of 11.7% and a 57.52% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Amgen, Esperion, and AbbVie.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Jazz Pharmaceuticals with a $257.14 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Jazz Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.07 billion and a net profit of $293.1 million. In comparison, last year the company earned a revenue of $897.84 million and had a GAAP net loss of $92.54 million

Based on the recent corporate insider activity of 89 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JAZZ in relation to earlier this year. Earlier this month, Samantha Pearce, the EVP & CCO of JAZZ sold 6,907.00 shares for a total of $1,625,976.87.

Read More on JAZZ:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).